AACR 2023 | The potential impact of lifileucel on the treatment landscape of melanoma

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, comments on the potential unmet needs lifileucel will fulfil in melanoma. For patients who progress on checkpoint inhibitors, there are limited treatment options, and the personalized nature of the adoptive T-cell therapy may provide a lifeline for this group of patients. The possible approval of lifileucel may additionally lead to the development of natural killer (NK) or CAR-T cell therapies in the future. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.